Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVHEHLMANN, Rüdiger; MÜLLER, Martin C; SCHNITTGER, Susanne et al.Journal of clinical oncology. 2014, Vol 32, Num 5, pp 415-423, issn 0732-183X, 9 p.Article

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVFABARIUS, Alice; LEITNER, Armin; JUNG-MUNKWITZ, Susanne et al.Blood. 2011, Vol 118, Num 26, pp 6760-6768, issn 0006-4971, 9 p.Article

Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm—Combined Prospective Analysis by the German AML IntergroupBÜCHNER, Thomas; SCHLENK, Richard F; SPÄTH, Daniela et al.Journal of clinical oncology. 2012, Vol 30, Num 29, pp 3604-3610, issn 0732-183X, 7 p.Article

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreHASFORD, Joerg; BACCARANI, Michele; SIMONSSON, Bengt et al.Blood. 2011, Vol 118, Num 3, pp 686-692, issn 0006-4971, 7 p.Article

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinibERNST, Thomas; GRUBER, Franz X; LANGE, Thoralf et al.Haematologica (Roma). 2009, Vol 94, Num 9, pp 1227-1235, issn 0390-6078, 9 p.Article

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemiaKREIL, Sebastian; PFIRRMANN, Markus; HAFERLACH, Claudia et al.Blood. 2007, Vol 110, Num 4, pp 1283-1290, issn 0006-4971, 8 p.Article

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferonHASFORD, Joerg; PFIRRMANN, Markus; SHEPHERD, Pat et al.Haematologica (Roma). 2005, Vol 90, Num 3, pp 335-340, issn 0390-6078, 6 p.Article

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid LeukemiaHEHLMANN, Rüdiger; LAUSEKER, Michael; HÄNEL, Mathias et al.Journal of clinical oncology. 2011, Vol 29, Num 12, pp 1634-1642, issn 0732-183X, 9 p.Article

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSAUSSELE, Susanne; LAUSEKER, Michael; SCHLIMOK, Günter et al.Blood. 2010, Vol 115, Num 10, pp 1880-1885, issn 0006-4971, 6 p.Article

Shedding of the endothelial glycocalyx during cardiac surgery: On-pump versus off-pump coronary artery bypass graft surgeryBRUEGGER, Dirk; REHM, Markus; ABICHT, Jan et al.Journal of thoracic and cardiovascular surgery (Print). 2009, Vol 138, Num 6, pp 1445-1447, issn 0022-5223, 3 p.Article

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study GroupLENZ, Georg; DREYLING, Martin; KNEBA, Michael et al.Blood. 2004, Vol 104, Num 9, pp 2667-2674, issn 0006-4971, 8 p.Article